Does ENZC fit the definition of A Pump and Dump?
First one would eed to idenitfy what a Pump and Dump is:
Pump-and-dump is a scheme that attempts to boost the price of a stock through recommendations based on false, misleading or greatly exaggerated statements. ... Then, once the price of the stock has been increased sufficiently by unsuspecting marks, the promoters then sell the stock at high prices.
So now the we know what a pump and dump is, ENZC clearly does not qualify.
So what is ENZC?
I'm glad you asked.
It is not a dotcom BOMB.
It is a RECENTLY organized combination of two (2) companies into one.
PLANO, TX / ACCESSWIRE / December 1, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") announced the execution of the definitive business combination agreement successfully merging the biotech companies Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. on World AIDS Day.
Through a merger of biotech companies, Enzolytics now advances two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the CoronaVirus. One technology, invented by Harry Zhabilov, the CSO of the Company, is a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. In these trials, the therapeutic, known as ITV-1, demonstrated effectiveness in the treatment of HIV patients in various stages of the disease. In trials conducted in 31 patients, the therapeutic showed efficacy, with 68% of those individuals tested experiencing an increase in CD4 + T lymphocytes. This increase was accompanied by an increase in the CD4/CD8 index and CD4% in over 50% of those tested. The increase in these parameters demonstrated statistical significance compared to the control group. The absolute number and the relative percent of CD8 + T lymphocytes were also decreased. And the viral load in 80.5% of those tested was below the threshold of detection. This Enzolytics anti-HIV treatment is now being advanced through the certification stage to thereafter be made available for patient therapy.
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics is committed to creating drugs for the better health of mankind.
Our mission is clear – to create therapeutics that are effective and affordable for treating infectious diseases that plague the world. This goal includes the development of therapeutics and monoclonal antibodies targeting infectious diseases, including the CoronaVirus. Our ultimate objective is to provide such therapeutics to improve health around the world.
Enzolytics, Inc. is a Texas-based biotech company committed to the development and commercialization of its proprietary proteins and monoclonal antibodies for the treatment of infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus and diphtheria. The Company’s multiple therapeutics also are being developed to treat Rheumatoid Arthritis and certain forms of cancer. Our technology for producing fully human monoclonal antibodies is now being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19.
OUR TECHNOLOGY
Enzolytics is a Texas-based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested its anti-HIV therapeutics known as ITV-1. ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union, where it demonstrated beneficial outcomes. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralize the HIV virus.
The Company’s scientific team, Harry Zhabilov, Joseph Cotropia MD, and Gaurav Chandra MD, pioneered the Company’s proprietary therapeutics for treating infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus, and diphtheria. The Company’s therapeutics may also be used to treat Rheumatoid Arthritis and certain forms of cancer.
The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases. One antibody (designated as CLONE 3) has been demonstrated in tests in 5 international labs to fully neutralize over 95% of all strains and viral subtypes of HIV-1 against which it has been tested.
These HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS. They may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current ARV therapy for several significant reasons: (1) the therapy will be effective and non-toxic, (2) will not require lifetime treatment, and (3) will be far less expensive.
Thus, for the patient, immunotherapy will be remarkably different — it will be safer, provide a much-needed immunotherapeutic cure rather than requiring lifelong treatment, and costs substantially less than current antiretroviral therapy.
The Company also has created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus, and diphtheria. As a part of its mission, the Company is testing these antibodies to prepare them for use as therapies against these diseases.
OUR SCIENCE
??
Enzolytics, Inc. is committed to the development and commercialization of its proprietary therapeutics for the treatment of debilitating infectious diseases. The Company’s technology is broad, including technology for treating HIV-1, Hepatitis (A, B, C), Rheumatoid Arthritis, certain forms of cancer, rabies, influenza A and B, tetanus, and diphtheria. The Company’s therapies are also being developed to treat chronic infection and certain forms of cancer.
As a result of the recent acquisition of the biotech company BioClonetics Immunotherapeutics, Inc., Enzolytics is now advancing additional complementary therapeutic platforms for treating infectious diseases, including a focus on the production of anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies to treat COVID-19.
Inactivated Pepsin Fragment (IPF) Technology
One Company technology, invented by Harry Zhabilov, the CSO of the Company, includes a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. This therapeutic, known as ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union. HIV patients tested in these trials showed the following beneficial outcomes:
Improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK, and of the index CD4/CD8.
Decrease in the viral load.
Demonstrated beneficial effect on opportunistic infections.
Demonstrated very good compatibility with all of the other modern antiretroviral drugs.
Demonstrated very good tolerance in all patients and complete absence of side effects.
This Enzolytics anti-HIV treatment is now being advanced through the certification stage, after which it will be available for patient therapy. ITV-1 also has also demonstrated a positive effect on different kinds of cancer due to its ability to stimulatesstimulate the immune system.
Fully Human Monoclonal Antibody Technology
With the recent acquisition of the technology created by BioClonetics Immunotherapeutics, Inc., the Company has additional and complementary technology for producing fully human monoclonal antibodies (mAbs) that neutralize the HIV virus. The Company is in the final development of the recombinant of the parent antibody (identified as “Clone 3”), which has been shown in in vitro tests conduction in 5 international laboratories to fully neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested. The basis for its broad-spectrum efficacy is the fact that Clone 3 mAb targets an immutable epitope on the HIV virus. The targeted epitope has remained present in 98% (either directly or by way of conserved substitutions) of all now known 87,336 HIV isolates analyzed by the Company’s use of artificial intelligence. The failure of other mAbs, such as the Vaccine Research Group VRC01 [Bar KJ, et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med. 2016;375(21):2037-50. PMCID|5292134] resulted from the targeting of mutable epitopes of the HIV virus.
Final testing of the Company’s anti-HIV mAb in PBMC neutralization assays is currently being completed, to be followed by animal trials at the California National Primate Research Center, UC Davis (Davis, CA).
The anti-HIV therapies of Enzolytics’ two technologies, that produced by Enzolytics and created at BioClonetics, are expected to be synergistic in treating HIV. Tests to establish such synergy are scheduled.
Anti-CoronaVirus Monoclonal Antibodies
The Company’s proprietary methodology may also be applied to produce monoclonal antibodies against other infectious diseases. This includes the production of monoclonal antibodies against the SARS-CoV-2 virus (CoronaVirus), as well as other infectious diseases, including HIV-2, anthrax, smallpox, H1N1 influenza, herpes zoster, varicella zoster, Rh (+) auto-immune disease, and the Ebolavirus. A Company program is underway to produce monoclonal antibodies against the SARS-CoV-2 virus (CoronaVirus). Such production will be achieved using the proprietary methodology used to previously produce monoclonal antibodies (mAbs) against HIV, rabies, influenza A, influenza B, tetanus, and diphtheria.
Having produced neutralizing antibodies against the HIV-1 virus and recognizing a significant correlative structure between the HIV virus and the SARS-CoV-2 virus, the Company is developing anti-SARS-Cov-2 (CoronaVirus) monoclonal antibodies using its proprietary technology. These antibodies are expected to provide a therapeutic for patients infected with COVID-19. Identification of these neutralizable epitopes also will permit the production of a phage display anti-SARS-CoV-2 (CoronaVirus) vaccine.
Production of these monoclonal antibodies is being conducted in the Company’s lab at the Texas A&M University Institute for Preclinical Studies in College Station, Texas.
INTELLECTUAL PROPERTY
The Company protects its technology through an aggressive strategy to cover its intellectual property. The Company’s intellectual property includes:
Issued Patents
Enzolytics is the owner of the following issued U.S. Patents covering its technology relating to a peptide that has been demonstrated in clinical trials to provide anti-HIV-1 retroviral benefit in vivo.
U.S. Patent No. 7,479,538, issued January 20, 2009, entitled Irreversibly-Inactivated Pepsinogen Fragment and Pharmaceutical Compositions Comprising the Same for Detecting, Preventing and Treating HIV
U.S. Patent No. 8,066,982, issued November 29, 2011, entitled Irreversibly-Inactivated Pepsinogen Fragment and Pharmaceutical Compositions Comprising the Same for Detecting, Preventing, and Treating HIV.
These patents cover an Inactivated Pepsin Fragment (IPF) identified and characterized by the amino acid sequence GDEPLENYLDTEYF. This peptide has demonstrated a significant in vitro binding affinity for HIV-1 gp 120 and gp 41 and human CD4 cells. The peptide exhibits antiretroviral activity in vivo, particularly anti-HIV-1 activity. IPF appears to modulate helper T1 cells’ expression of elaborate cytokines INFy, IL-2, which selectively promote cell-mediated immune response and subsequently stimulate cytotoxic lymphocytes. These lymphocytes have a prominent role in the host’s immunologic response to HIV infection. Proteins encoded by these pathogens enter the endogenous pathway for antigen presentation and are expressed on the surface of the infected cell as a complex with class I MHC – proteins. IPF appears to present a novel mechanism to reduce the viral burden and stimulate innate immune responses to the virus for patients with significant antiretroviral resistance.
Proprietary Cell Line Producing Clone 3 anti-HIV monoclonal antibody
The Company’s Clone 3 cell line, which produces fully human monoclonal antibodies (mAbs) that specifically target and neutralize the HIV-1 virus, is proprietary to the Company.
Pending Patent Applications
The Company has the following pending patents covering its anti-HIV monoclonal antibody technology:
Pending Patent covering the recombinant of the Clone 3 antibody. This form of the Clone 3 antibody is prepared using the known amino acid sequence of the antibody in conjunction with a high producing CHO cell line for generating recombinant form of the monoclonal antibodies that will ultimately be used in patient application.
Pending Patent coverage of small molecules (mini-peptides) for commercial use derived from the structure of the Clone 3 antibody for interrupting and preventing binding between the HIV virus and the human CD4+ cell.
Coverage is directed to blocking peptides that bind to and neutralize the HIV virus, and
Competitive peptides that bind to the target CD4+ cells at the point of virus access into the human cell to prevent infection.
Pending Patent covering the proprietary methodology for producing fully human neutralizing monoclonal antibodies against infectious diseases, including Rabies, influenza A, influenza B, Tetanus, Diphtheria, HIV-2, Anthrax, Smallpox, H1N1 influenza, Herpes Zoster, Varicella Zoster and Ebola.
Pending Patent covering the proprietary methodology for produced anti-antigen monoclonal antibodies to produce vaccines to achieve a broad and durable humoral protective antibody response against the corresponding infectious agent.
Proprietary Methodology for Producing Fully Human Monoclonal Antibodies
The Company proprietary mAb methodologies & immunotherapeutic technologies platform will be used to create therapeutics for treatments of viral infectious diseases against:
HIV-2
Anthrax
Smallpox
H1N1 Influenza
Herpes Zoster
Varicella Zoster
Ebola
The Company antibody-based immunotherapeutic platform can be utilized for both human and all animal infectious-disease applications.
In addition to the anti-HIV monoclonal antibodies produced by the Company, the Company currently has also produced fully human monoclonal antibodies against:
Rabies
Influenza A
Influenza B
Tetanus
Diphtheria
The Significance of the Methodology for Producing Fully Human Therapeutic Monoclonal Antibodies
Biologics, specifically fully human neutralizing monoclonal antibodies directed against infectious disease, is considered the new frontier in biotechnology. In the past, the initial starting products were “humanized” rat and mouse mAbs being created for therapeutic use. “Humanized” immunoglobulins are the major immunotherapeutic that is prevalent today. What sets the Company’s antibody technology apart from that employed by other pharma? The Company’s technology permits the cloning of human or animal immune system cells. With the Company’s proprietary methodologies, stable parent hybridomas cell lines can be created that produce fully human antibodies.
Enzolytics specializes in the creation of human neutralizing monoclonal antibodies, not “humanized” mouse or rat counterparts, as are many mAb therapeutics in pharmaceutical use today. The Company’s technological methodologies have developed an effective, strong, and robust portfolio of biologics that have a pharmaceutical application with significant benefits to patients or animals in the global marketplace. From an identified and created parent hybridoma cell line, four distinct and effective products can be produced: (1) fully human neutralizing monoclonal antibody—directed against any pathogen based disease entity—through use in passive immunotherapy; (2) an effective humoral active vaccine that is safe and effective; (3) an oral mini-antibody peptide-based medication with an efficacy that is equivalent to the immunologic capacity of the monoclonal antibody produced by parent hybridoma cell; and (4) an entry-fusion inhibitor that is immunologic in character and scope. The applications are broad, effective, and beneficial for immunotherapeutic use.
The methodologies and processes for creating immortalized cells that stably produce human monoclonal antibodies are Company proprietary trade secrets.
Anti-HIV Technology and Products
Using its proprietary technology, The Company has created a proprietary cell line that produces a fully human monoclonal antibody (known as Clone 3) that specifically targets and neutralizes the HIV virus (i.e., renders the virus incapable of reproduction). This capability to neutralize the virus means that Clone 3 may be used successfully to treat those infected with HIV and provide an ideal immunogen in the development of an active anti-HIV/AIDS vaccine that is both prophylactic and therapeutic.
Additional supplemental products may be produced as well, for example, vaginal creams for prevention of transmission of the virus. Additionally, Clone 3 has the potential to enormously reduce the incidence of mother-to-child transmission (MTCT) of the virus. Not only might it prevent in-utero viral transmission but, postnatally, effective treatment can be administered without fear of antiretroviral (ARV) toxicity or resistance.
Each of these distinct products flows from the Company’s technology. The first is the use of the antibody itself or a recombinant of the antibody. The second is the Clone 3 vaccine, the third is a mini-antibody or paratope of the Clone 3 antibody, and the fourth is a competitive binding entry-fusion inhibitor that prevents infectivity.
In addition to the Clone 3 monoclonal antibody against HIV, the Company has also created human monoclonal antibodies against other infectious diseases, including rabies, influenza A, influenza B, tetanus, and diphtheria. This immunotherapeutic technology platform can be readily applied to creating monoclonal antibodies against other pathogenic diseases, including the SARAS-CoV-2 (CoronaVirus), HIV-2, anthrax, smallpox, H1N1 influenza, herpes zoster, varicella zoster, Rh (+) auto=immune disease, and the Ebolavirus. The Company’s antibody-based Immunotherapeutics platform can be utilized across both human and animal infectious-disease applications. For example, the technology can be used to produce treatment for elephant and equine diseases that threaten these species.
AI
